|Bid||51.49 x 1100|
|Ask||51.63 x 4000|
|Day's Range||50.50 - 53.14|
|52 Week Range||42.51 - 169.76|
|Beta (5Y Monthly)||2.01|
|PE Ratio (TTM)||11.00|
|Earnings Date||May 09, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||121.86|
Subscribe to Yahoo Finance Plus to view Fair Value for CRSP
Shares of Editas Medicine (NASDAQ: EDIT), a genome editing biotech company that uses CRISPR/Cas9 and CRISPR/Cas12a genome editing systems to develop therapies, saw its shares plummet 28.9% this week, according to data from S&P Global Market Intelligence. Editas' shares have steadily fallen this year, but it is hardly alone among gene-editing companies. Intellia Therapeutics is down more than 63% so far this year while CRISPR Therapeutics has seen its shares drop more than 38%.
Let's look at two stocks that boast significant upside potential, going by average price targets set by analysts on the street: Moderna (NASDAQ: MRNA) and CRISPR Therapeutics (NASDAQ: CRSP). Biotech giant Moderna fell along with the broader market in recent months. Moderna currently generates revenue from just one product: its coronavirus vaccine.
Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.